

DANG Lei (M.Phil.)

Academic qualifications:

- 2007-2011: B. Sc. Guangzhou University of Chinese Medicine, Guangzhou, China
2014-2016: M. Phil. Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University & Teaching Division, School of Chinese Medicine, Hong Kong Baptist University

Previous academic positions held:

- 2011-2012: Researcher, Guangzhou General Pharmaceutical Research Institute
2012-2014: Research Assistant, Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University & Teaching Division, School of Chinese Medicine, Hong Kong Baptist University

Present academic position:

- 2016-now: Ph.D. student, Institute for Advancing Translational Medicine in Bone & Joint Diseases, Hong Kong Baptist University, China

Previous relevant research work:

Molecular understandings and RNAi-based & phytotherapy-based translational research in bone & joints diseases.

Publication records:

Section A-Five most representative publications in the recent five years (* Corresponding Author)

1. Liu J., Li D., **Dang L. (co-author)**, Liang C., Guo B., Lu C., He X., Cheung H., He B., Liu B., Li F., Lu J., Wang L., Shaikh B., Jiang F., Lu C., Peng S., Zhang Z., Zhang B., Pan X., Xiao L., Lu A.P., Zhang G. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. *Sci Rep*. 2017 Jan; doi: 10.1038/srep40487.
2. Wang L., Li F., **Dang L. (co-author)**, Liang C., Wang C., He B., Liu J., Li D., Wu X., Xu X., Lu A.P., Zhang G. In Vivo Delivery Systems for Therapeutic Genome Editing. *Int J Mol Sci*. 2016 April; doi:10.3390/ijms17050626.
3. Li D., Liu J., Guo B., Liang C., **Dang L.**, Lu C., He X., Cheung H., Xu L., Lu C., He B., Liu B., Shaikh A., Li F., Wang L., Yang Z., Au D.W., Peng S., Zhang Z., Zhang B., Pan X., Qian A., Shang P., Xiao L., Jiang B., Wong C., Xu J., Bian Z., Liang Z., Guo D. Zhu H., Tan W., Lu A., Zhang G. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. *Nat Commun*. 2016 March; doi: 10.1038/ncomms10872.
4. **Dang L. (co-author)**, Liu J., Li F., Wang L., Li D., Guo B., He X., Jiang F., Liang C., Liu B., Badshah S., Lu J., Lu C., Lu A., Zhang G. Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders. *Int J Mol Sci*. 2016 March; doi:10.3390/ijms17030428.
5. Liu J., **Dang L. (co-author)**, Li D., Liang C., He X., Wu H., Qian A., Yang Z., Au DW, Chiang MW, Zhang BT, Han Q., Yue KK, Zhang H., Lv C., Pan X., Xu J., Bian Z., Shang P., Tan W., Liang Z., Guo B., Lu A., Zhang G. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. *Biomaterials*. 2015 Feb; 52:148-160.

Section B - Five representative publications beyond the recent five-year period with the latest publication entered first

N/A

Award:

Dang L, Shaikh AB. Osteoblastic Plekho1 contributes to articular inflammation and bone repair failure in rheumatoid arthritis. **The Third Prize**. The National Competition – Hong Kong Regional Final – Hong Kong University Student Innovation and Entrepreneurship Competition 2017, Hong Kong, China, 2017

Dang L, Liu J., Li D.F. A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of MicroRNAs in Osteoclasts. **The Second Prize**. "Entrepreneurship Challenge Cup" - China Competition - Hong Kong stage, Hong Kong, China, 2016

Dang L, Guo B, Li D,...,Lu A, Zhang G. A Peptide-functionalized delivery system to target osteoclasts. ASBMR2014. Poster Presentation Abstract. **Young Investigator Travel Grant Award**. American Society for Bone and Mineral Research. Houston, USA, 2014

Patent:

N/A

Funded Projects

N/A